Work

Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)

Year: 2015

Type: article

Source: Blood

DOI: 10.1182/blood.v126.23.1609.1609

Authors: Ruben A. Mesa, Claire N. Harrison, Francisco Cervantes, James P. Dean, Lixia Wang, Tanya Granston, Yoojung Yang, Alessandro M. Vannucchi, Adam Mead

Institutions: Mayo Clinic, Mayo Clinic in Arizona, Guy's and St Thomas' NHS Foundation Trust, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona, CTI BioPharma (United States), University of Florence, University of Oxford, Oxford University Hospitals NHS Trust

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics (clinical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2979663993

FWCI:

Cites:

Cited by:

Related to: 10